 Risk adverse events children treatment acute lymphoblastic leukemia Jude Total Therapy studies VIII IX frequency predictors adverse events patients treatment acute lymphoblastic leukemia consecutive total therapy studies VII IX Event-free survival study overall studies VIII IX log-rank test study patients therapy studies VIII IX risks adverse event first years completion therapy similar confidence interval study studies VIII IX Bone marrow testicular CNS relapses majority failures groups study studies VIII IX Late adverse events hematologic relapses development solid tumors Black race anterior mediastinal mass risk failure completion treatment clinical trials leukemic cell DNA content DNA index predictor late treatment failure recent trial None presenting features eg age leukocyte count sex value predictors late failure Thus treatment impact specific prognostic factors distribution sites relapse risk delayed failure